[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601517":3},{"organization":4,"armGroups":7,"interventions":72,"overallOfficials":90,"centralContacts":94,"locations":101,"responsibleParty":689,"collaborators":691,"id":694,"slug":695,"hasResults":696,"nctId":697,"briefTitle":698,"officialTitle":699,"acronym":78,"eligibilityCriteria":700,"healthyVolunteers":696,"sex":701,"minAge":702,"maxAge":78,"enrollmentInfo":703,"targetDuration":78,"studyType":706,"phases":707,"briefSummary":710,"conditions":711,"keywords":713,"overallStatus":104,"whyStopped":78,"lastUpdateSubmitDate":727,"lastUpdatePostDateStruct":728,"startDateStruct":731,"completionDateStruct":733,"leadSponsor":735,"locationsCount":736},{"fullName":5,"class":6},"BioNTech SE","INDUSTRY",[8,15,19,22,26,29,33,37,41,45,49,53,59,63,67],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 - BNT326 (DL1, starting dose) + BNT327","EXPERIMENTAL","Combination therapy of BNT326 and BNT327. In participants with second-line (or higher) 2L(+), squamous or non-squamous NSCLC, actionable genomic alterations (AGA)-negative\u002Fpositive, any PD-L1.",[13,14],"Drug: BNT326","Drug: BNT327",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1 - BNT326 (DL2) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 2L(+), squamous or non-squamous NSCLC, AGA-negative\u002Fpositive, any PD-L1.",[13,14],{"label":20,"type":10,"description":17,"interventionNames":21},"Part 1 - BNT326 (DL3, optional) + BNT327",[13,14],{"label":23,"type":10,"description":24,"interventionNames":25},"Part 2a (Cohort A, Arm 1) - BNT326 (DL1) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 2L+ squamous or non-squamous NSCLC, AGA-negative\u002Fpositive, any PD-L1.",[13,14],{"label":27,"type":10,"description":24,"interventionNames":28},"Part 2a (Cohort A, Arm 2) - BNT326 (DL2) + BNT327",[13,14],{"label":30,"type":10,"description":31,"interventionNames":32},"Part 2a (Cohort B, Arm 1) - BNT326 (DL1) + BNT327","Combination therapy of BNT326 and BNT327. In participants with first-line (1L) squamous or non-squamous NSCLC, AGA-negative, any PD-L1.",[13,14],{"label":34,"type":10,"description":35,"interventionNames":36},"Part 2a (Cohort B, Arm 2) - BNT326 (DL2) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 1L squamous or non-squamous NSCLC, AGA-negative, any PD-L1.",[13,14],{"label":38,"type":10,"description":39,"interventionNames":40},"Part 2b (Cohort C, Arm 1) - BNT326 (DL1) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or epithelial growth factor receptor (EGFR) activating mutation, any PD-L1.",[13,14],{"label":42,"type":10,"description":43,"interventionNames":44},"Part 2b (Cohort C, Arm 2) - BNT326 (DL2) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1.",[13,14],{"label":46,"type":10,"description":47,"interventionNames":48},"Part 2b (Cohort C, Arm 3) - BNT326 monotherapy","BNT326 monotherapy (DL2). In participants with 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1.",[13],{"label":50,"type":10,"description":51,"interventionNames":52},"Part 2b (Cohort D1, Arm 1) - BNT326 (DL2) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.",[13,14],{"label":54,"type":55,"description":56,"interventionNames":57},"Part 2b (Cohort D1, Arm 2) - Pembrolizumab","ACTIVE_COMPARATOR","Pembrolizumab monotherapy. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.",[58],"Drug: Pembrolizumab",{"label":60,"type":10,"description":61,"interventionNames":62},"Part 2b (Cohort D1, Arm 3) - BNT327 monotherapy","BNT327 monotherapy. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50%.",[14],{"label":64,"type":10,"description":65,"interventionNames":66},"Part 2b (Cohort D2, Arm 1) - BNT326 (DL2) + BNT327","Combination therapy of BNT326 and BNT327. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 \\\u003C50%.",[13,14],{"label":68,"type":55,"description":69,"interventionNames":70},"Part 2b (Cohort D2, Arm 2) - SoC - Pembrolizumab + chemotherapy","Combination therapy of pembrolizumab and chemotherapy. In participants with 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 \\\u003C50%.",[58,71],"Drug: SoC",[73,79,83,86],{"type":74,"name":75,"description":76,"armGroupLabels":77,"otherNames":78},"DRUG","BNT326","intravenous (IV) infusion",[9,16,20,23,27,30,34,38,42,46,50,64],null,{"type":74,"name":80,"description":81,"armGroupLabels":82,"otherNames":78},"BNT327","IV infusion",[9,16,20,23,27,30,34,38,42,50,60,64],{"type":74,"name":84,"description":81,"armGroupLabels":85,"otherNames":78},"Pembrolizumab",[54,68],{"type":74,"name":87,"description":88,"armGroupLabels":89,"otherNames":78},"SoC","IV infusion. Combination chemotherapy (pemetrexed, paclitaxel, or carboplatin). Chemotherapy will be selected according to the indication.",[68],[91],{"name":92,"affiliation":5,"role":93},"BioNTech Responsible Person","STUDY_DIRECTOR",[95],{"name":96,"role":97,"phone":98,"phoneExt":99,"email":100},"BioNTech clinical trials patient information","CONTACT","+49 6131 9084","0","patients@biontech.de",[102,116,126,136,146,156,165,175,185,195,206,215,224,233,244,253,262,271,280,289,295,304,309,315,321,330,339,344,353,362,367,376,385,394,403,412,421,432,441,452,461,472,483,492,498,507,518,527,533,539,548,557,567,573,579,588,594,600,606,615,624,630,636,645,654,665,671,680],{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":78},"Stanford Cancer Institute","RECRUITING","Stanford","California","94305","United States","US",{"type":111,"coordinates":112},"Point",[113,114],-122.16608,37.42411,{"lat":114,"lon":113},{"facility":117,"status":104,"city":118,"state":119,"zip":120,"country":108,"countryCode":109,"cosmosGeoPoint":121,"geoPoint":125,"contacts":78},"Yale University","New Haven","Connecticut","06511",{"type":111,"coordinates":122},[123,124],-72.92816,41.30815,{"lat":124,"lon":123},{"facility":127,"status":104,"city":128,"state":129,"zip":130,"country":108,"countryCode":109,"cosmosGeoPoint":131,"geoPoint":135,"contacts":78},"Moffit Cancer Center","Tampa","Florida","33612",{"type":111,"coordinates":132},[133,134],-82.45843,27.94752,{"lat":134,"lon":133},{"facility":137,"status":104,"city":138,"state":139,"zip":140,"country":108,"countryCode":109,"cosmosGeoPoint":141,"geoPoint":145,"contacts":78},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":111,"coordinates":142},[143,144],-71.05977,42.35843,{"lat":144,"lon":143},{"facility":147,"status":104,"city":148,"state":149,"zip":150,"country":108,"countryCode":109,"cosmosGeoPoint":151,"geoPoint":155,"contacts":78},"Henry Ford Health System","Detroit","Michigan","48202",{"type":111,"coordinates":152},[153,154],-83.04575,42.33143,{"lat":154,"lon":153},{"facility":157,"status":104,"city":158,"state":158,"zip":159,"country":108,"countryCode":109,"cosmosGeoPoint":160,"geoPoint":164,"contacts":78},"Memorial Sloan Kettering Cancer Center","New York","10065",{"type":111,"coordinates":161},[162,163],-74.00597,40.71427,{"lat":163,"lon":162},{"facility":166,"status":104,"city":167,"state":168,"zip":169,"country":108,"countryCode":109,"cosmosGeoPoint":170,"geoPoint":174,"contacts":78},"Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center","Cleveland","Ohio","44195",{"type":111,"coordinates":171},[172,173],-81.69541,41.4995,{"lat":173,"lon":172},{"facility":176,"status":104,"city":177,"state":178,"zip":179,"country":108,"countryCode":109,"cosmosGeoPoint":180,"geoPoint":184,"contacts":78},"University of Texas M. D. Anderson Cancer Center","Houston","Texas","77030",{"type":111,"coordinates":181},[182,183],-95.36327,29.76328,{"lat":183,"lon":182},{"facility":186,"status":104,"city":187,"state":188,"zip":189,"country":108,"countryCode":109,"cosmosGeoPoint":190,"geoPoint":194,"contacts":78},"NEXT Virginia","Fairfax","Virginia","22031",{"type":111,"coordinates":191},[192,193],-77.30637,38.84622,{"lat":193,"lon":192},{"facility":196,"status":104,"city":197,"state":78,"zip":198,"country":199,"countryCode":200,"cosmosGeoPoint":201,"geoPoint":205,"contacts":78},"Cancer Research SA","Adelaide","5000","Australia","AU",{"type":111,"coordinates":202},[203,204],138.59863,-34.92866,{"lat":204,"lon":203},{"facility":207,"status":104,"city":208,"state":78,"zip":209,"country":199,"countryCode":200,"cosmosGeoPoint":210,"geoPoint":214,"contacts":78},"St George Private Hospital","Kogarah","2217",{"type":111,"coordinates":211},[212,213],151.13564,-33.9681,{"lat":213,"lon":212},{"facility":216,"status":104,"city":217,"state":78,"zip":218,"country":199,"countryCode":200,"cosmosGeoPoint":219,"geoPoint":223,"contacts":78},"John Flynn Private Hospital","Tugun","4224",{"type":111,"coordinates":220},[221,222],153.5,-28.15,{"lat":222,"lon":221},{"facility":225,"status":104,"city":226,"state":78,"zip":227,"country":199,"countryCode":200,"cosmosGeoPoint":228,"geoPoint":232,"contacts":78},"Westmead Hospital","Westmead","2145",{"type":111,"coordinates":229},[230,231],150.98768,-33.80383,{"lat":231,"lon":230},{"facility":234,"status":104,"city":235,"state":78,"zip":236,"country":237,"countryCode":238,"cosmosGeoPoint":239,"geoPoint":243,"contacts":78},"Affiliated Hospital of Hebei University","Baoding","071000","China","CN",{"type":111,"coordinates":240},[241,242],115.46246,38.87288,{"lat":242,"lon":241},{"facility":245,"status":104,"city":246,"state":78,"zip":247,"country":237,"countryCode":238,"cosmosGeoPoint":248,"geoPoint":252,"contacts":78},"Beijing GoBroad Hospital","Beijing","102200",{"type":111,"coordinates":249},[250,251],116.39723,39.9075,{"lat":251,"lon":250},{"facility":254,"status":104,"city":255,"state":78,"zip":256,"country":237,"countryCode":238,"cosmosGeoPoint":257,"geoPoint":261,"contacts":78},"The First Hospital of Jilin University","Changchun","130021",{"type":111,"coordinates":258},[259,260],125.32278,43.88,{"lat":260,"lon":259},{"facility":263,"status":104,"city":264,"state":78,"zip":265,"country":237,"countryCode":238,"cosmosGeoPoint":266,"geoPoint":270,"contacts":78},"West China Hospital, Sichuan University","Chengdu","611135",{"type":111,"coordinates":267},[268,269],104.06667,30.66667,{"lat":269,"lon":268},{"facility":272,"status":104,"city":273,"state":78,"zip":274,"country":237,"countryCode":238,"cosmosGeoPoint":275,"geoPoint":279,"contacts":78},"Chongqing University Cancer Hospital","Chongqing","400030",{"type":111,"coordinates":276},[277,278],106.55771,29.56026,{"lat":278,"lon":277},{"facility":281,"status":104,"city":282,"state":78,"zip":283,"country":237,"countryCode":238,"cosmosGeoPoint":284,"geoPoint":288,"contacts":78},"The First Affiliated Hospital School of Clinical Medicine of Guangdong Pharmaceutical University","Guangzhou","510080",{"type":111,"coordinates":285},[286,287],113.25,23.11667,{"lat":287,"lon":286},{"facility":290,"status":104,"city":282,"state":78,"zip":291,"country":237,"countryCode":238,"cosmosGeoPoint":292,"geoPoint":294,"contacts":78},"The First Affiliated Hospital of Guangzhou Medical University","510163",{"type":111,"coordinates":293},[286,287],{"lat":287,"lon":286},{"facility":296,"status":104,"city":297,"state":78,"zip":298,"country":237,"countryCode":238,"cosmosGeoPoint":299,"geoPoint":303,"contacts":78},"Anhui Chest Hospital","Hefei","230022",{"type":111,"coordinates":300},[301,302],117.28083,31.86389,{"lat":302,"lon":301},{"facility":305,"status":104,"city":297,"state":78,"zip":298,"country":237,"countryCode":238,"cosmosGeoPoint":306,"geoPoint":308,"contacts":78},"The First Affiliated Hospital of Anhui Medical University",{"type":111,"coordinates":307},[301,302],{"lat":302,"lon":301},{"facility":310,"status":104,"city":297,"state":78,"zip":311,"country":237,"countryCode":238,"cosmosGeoPoint":312,"geoPoint":314,"contacts":78},"Anhui Provincial Cancer Hospital","230088",{"type":111,"coordinates":313},[301,302],{"lat":302,"lon":301},{"facility":316,"status":104,"city":297,"state":78,"zip":317,"country":237,"countryCode":238,"cosmosGeoPoint":318,"geoPoint":320,"contacts":78},"The Second Hospital of Anhui Medical University","230601",{"type":111,"coordinates":319},[301,302],{"lat":302,"lon":301},{"facility":322,"status":104,"city":323,"state":78,"zip":324,"country":237,"countryCode":238,"cosmosGeoPoint":325,"geoPoint":329,"contacts":78},"Jinan Central Hospital","Jinan","250013",{"type":111,"coordinates":326},[327,328],116.99722,36.66833,{"lat":328,"lon":327},{"facility":331,"status":104,"city":332,"state":78,"zip":333,"country":237,"countryCode":238,"cosmosGeoPoint":334,"geoPoint":338,"contacts":78},"The First Affiliated Hospital of Nanchang University","Nanchang","330006",{"type":111,"coordinates":335},[336,337],115.85306,28.68396,{"lat":337,"lon":336},{"facility":340,"status":104,"city":332,"state":78,"zip":333,"country":237,"countryCode":238,"cosmosGeoPoint":341,"geoPoint":343,"contacts":78},"The Second Affiliated Hospital of Nanchang University",{"type":111,"coordinates":342},[336,337],{"lat":337,"lon":336},{"facility":345,"status":104,"city":346,"state":78,"zip":347,"country":237,"countryCode":238,"cosmosGeoPoint":348,"geoPoint":352,"contacts":78},"The Affiliated Hospital of Qingdao University","Qingdao","266003",{"type":111,"coordinates":349},[350,351],120.38042,36.06488,{"lat":351,"lon":350},{"facility":354,"status":104,"city":355,"state":78,"zip":356,"country":237,"countryCode":238,"cosmosGeoPoint":357,"geoPoint":361,"contacts":78},"Shanghai East Hospital","Shanghai","200120",{"type":111,"coordinates":358},[359,360],121.45806,31.22222,{"lat":360,"lon":359},{"facility":363,"status":104,"city":355,"state":78,"zip":356,"country":237,"countryCode":238,"cosmosGeoPoint":364,"geoPoint":366,"contacts":78},"Shanghai GoBroad Cancer Hospital",{"type":111,"coordinates":365},[359,360],{"lat":360,"lon":359},{"facility":368,"status":104,"city":369,"state":78,"zip":370,"country":237,"countryCode":238,"cosmosGeoPoint":371,"geoPoint":375,"contacts":78},"The First Affiliated Hospital of Soochow University","Suzhou","215006",{"type":111,"coordinates":372},[373,374],120.59538,31.30408,{"lat":374,"lon":373},{"facility":377,"status":104,"city":378,"state":78,"zip":379,"country":237,"countryCode":238,"cosmosGeoPoint":380,"geoPoint":384,"contacts":78},"Tianjin Medical University Cancer Institute & Hospital","Tianjin","300060",{"type":111,"coordinates":381},[382,383],117.17667,39.14222,{"lat":383,"lon":382},{"facility":386,"status":104,"city":387,"state":78,"zip":388,"country":237,"countryCode":238,"cosmosGeoPoint":389,"geoPoint":393,"contacts":78},"Hubei Cancer Hospital","Wuhan","430079",{"type":111,"coordinates":390},[391,392],114.26667,30.58333,{"lat":392,"lon":391},{"facility":395,"status":104,"city":396,"state":78,"zip":397,"country":237,"countryCode":238,"cosmosGeoPoint":398,"geoPoint":402,"contacts":78},"Xiangyang Central Hospital","Xiangyang","441138",{"type":111,"coordinates":399},[400,401],112.14479,32.0422,{"lat":401,"lon":400},{"facility":404,"status":104,"city":405,"state":78,"zip":406,"country":237,"countryCode":238,"cosmosGeoPoint":407,"geoPoint":411,"contacts":78},"The First Affiliated Hospital of Xinxiang Medical University","Xinxiang","453100",{"type":111,"coordinates":408},[409,410],113.80151,35.19033,{"lat":410,"lon":409},{"facility":413,"status":104,"city":414,"state":78,"zip":415,"country":237,"countryCode":238,"cosmosGeoPoint":416,"geoPoint":420,"contacts":78},"Northern Jiangsu People's Hospital","Yangzhou","225001",{"type":111,"coordinates":417},[418,419],119.43583,32.39722,{"lat":419,"lon":418},{"facility":422,"status":104,"city":423,"state":78,"zip":424,"country":425,"countryCode":426,"cosmosGeoPoint":427,"geoPoint":431,"contacts":78},"Universitätsklinikum Carl Gustav Carus TU Dresden","Dresden","01307","Germany","DE",{"type":111,"coordinates":428},[429,430],13.73832,51.05089,{"lat":430,"lon":429},{"facility":433,"status":104,"city":434,"state":78,"zip":435,"country":425,"countryCode":426,"cosmosGeoPoint":436,"geoPoint":440,"contacts":78},"Universitätsklinikum Freiburg","Freiburg im Breisgau","79106",{"type":111,"coordinates":437},[438,439],7.85222,47.9959,{"lat":439,"lon":438},{"facility":442,"status":104,"city":443,"state":78,"zip":444,"country":445,"countryCode":446,"cosmosGeoPoint":447,"geoPoint":451,"contacts":78},"Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo","Alessandria","15100","Italy","IT",{"type":111,"coordinates":448},[449,450],8.61007,44.90924,{"lat":450,"lon":449},{"facility":453,"status":104,"city":454,"state":78,"zip":455,"country":445,"countryCode":446,"cosmosGeoPoint":456,"geoPoint":460,"contacts":78},"Azienda Ospedaliera Universitaria Careggi","Florence","50134",{"type":111,"coordinates":457},[458,459],11.24626,43.77925,{"lat":459,"lon":458},{"facility":462,"status":104,"city":463,"state":78,"zip":464,"country":465,"countryCode":466,"cosmosGeoPoint":467,"geoPoint":471,"contacts":78},"Institute of Oncology, ARENSIA Exploratory Medicine","Chisinau","2025","Moldova","MD",{"type":111,"coordinates":468},[469,470],28.85938,47.00902,{"lat":470,"lon":469},{"facility":473,"status":104,"city":474,"state":78,"zip":475,"country":476,"countryCode":477,"cosmosGeoPoint":478,"geoPoint":482,"contacts":78},"Pratia MCM Krakow","Krakow","30-727","Poland","PL",{"type":111,"coordinates":479},[480,481],19.93658,50.06143,{"lat":481,"lon":480},{"facility":484,"status":104,"city":485,"state":78,"zip":486,"country":476,"countryCode":477,"cosmosGeoPoint":487,"geoPoint":491,"contacts":78},"Centrum Medyczne Pratia Poznan","Poznan","60-192",{"type":111,"coordinates":488},[489,490],16.92993,52.40692,{"lat":490,"lon":489},{"facility":493,"status":104,"city":485,"state":78,"zip":494,"country":476,"countryCode":477,"cosmosGeoPoint":495,"geoPoint":497,"contacts":78},"Med-Polonia Sp. z o.o.","60-693",{"type":111,"coordinates":496},[489,490],{"lat":490,"lon":489},{"facility":499,"status":104,"city":500,"state":78,"zip":501,"country":476,"countryCode":477,"cosmosGeoPoint":502,"geoPoint":506,"contacts":78},"Provita Prolife","Tomaszów Mazowiecki","97-200",{"type":111,"coordinates":503},[504,505],20.00855,51.53131,{"lat":505,"lon":504},{"facility":508,"status":104,"city":509,"state":78,"zip":510,"country":511,"countryCode":512,"cosmosGeoPoint":513,"geoPoint":517,"contacts":78},"Hospital Clinic de Barcelona","Barcelona","08036","Spain","ES",{"type":111,"coordinates":514},[515,516],2.15899,41.38879,{"lat":516,"lon":515},{"facility":519,"status":104,"city":520,"state":78,"zip":521,"country":511,"countryCode":512,"cosmosGeoPoint":522,"geoPoint":526,"contacts":78},"Hospital Universitario 12 de Octubre","Madrid","28041",{"type":111,"coordinates":523},[524,525],-3.70256,40.4165,{"lat":525,"lon":524},{"facility":528,"status":104,"city":520,"state":78,"zip":529,"country":511,"countryCode":512,"cosmosGeoPoint":530,"geoPoint":532,"contacts":78},"Hospital Universitario HM Madrid Sanchinarro","28050",{"type":111,"coordinates":531},[524,525],{"lat":525,"lon":524},{"facility":534,"status":104,"city":520,"state":78,"zip":535,"country":511,"countryCode":512,"cosmosGeoPoint":536,"geoPoint":538,"contacts":78},"Clinica Universidad de Navarra","31008",{"type":111,"coordinates":537},[524,525],{"lat":525,"lon":524},{"facility":540,"status":104,"city":541,"state":78,"zip":542,"country":511,"countryCode":512,"cosmosGeoPoint":543,"geoPoint":547,"contacts":78},"Hospital Quironsalud Malaga","Málaga","29004",{"type":111,"coordinates":544},[545,546],-4.42034,36.72016,{"lat":546,"lon":545},{"facility":549,"status":104,"city":550,"state":78,"zip":551,"country":511,"countryCode":512,"cosmosGeoPoint":552,"geoPoint":556,"contacts":78},"Hospital Universitario Virgen Macarena","Seville","41009",{"type":111,"coordinates":553},[554,555],-5.97317,37.38283,{"lat":555,"lon":554},{"facility":558,"status":104,"city":559,"state":78,"zip":560,"country":561,"countryCode":78,"cosmosGeoPoint":562,"geoPoint":566,"contacts":78},"Medical Park Seyhan Hospital","Adana","01140","Turkey (Türkiye)",{"type":111,"coordinates":563},[564,565],35.32531,36.98615,{"lat":565,"lon":564},{"facility":568,"status":104,"city":559,"state":78,"zip":569,"country":561,"countryCode":78,"cosmosGeoPoint":570,"geoPoint":572,"contacts":78},"Adana City Hospital","01230",{"type":111,"coordinates":571},[564,565],{"lat":565,"lon":564},{"facility":574,"status":104,"city":559,"state":78,"zip":575,"country":561,"countryCode":78,"cosmosGeoPoint":576,"geoPoint":578,"contacts":78},"Baskent University Adana Application and Research Center","01240",{"type":111,"coordinates":577},[564,565],{"lat":565,"lon":564},{"facility":580,"status":104,"city":581,"state":78,"zip":582,"country":561,"countryCode":78,"cosmosGeoPoint":583,"geoPoint":587,"contacts":78},"Hacettepe University Medical Faculty","Ankara","06100",{"type":111,"coordinates":584},[585,586],32.85427,39.91987,{"lat":586,"lon":585},{"facility":589,"status":104,"city":581,"state":78,"zip":590,"country":561,"countryCode":78,"cosmosGeoPoint":591,"geoPoint":593,"contacts":78},"Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Clinical Research Center","06105",{"type":111,"coordinates":592},[585,586],{"lat":586,"lon":585},{"facility":595,"status":104,"city":581,"state":78,"zip":596,"country":561,"countryCode":78,"cosmosGeoPoint":597,"geoPoint":599,"contacts":78},"Gazi University Medical Faculty","06500",{"type":111,"coordinates":598},[585,586],{"lat":586,"lon":585},{"facility":601,"status":104,"city":581,"state":78,"zip":602,"country":561,"countryCode":78,"cosmosGeoPoint":603,"geoPoint":605,"contacts":78},"Ankara Memorial Hospital","06520",{"type":111,"coordinates":604},[585,586],{"lat":586,"lon":585},{"facility":607,"status":104,"city":608,"state":78,"zip":609,"country":561,"countryCode":78,"cosmosGeoPoint":610,"geoPoint":614,"contacts":78},"Memorial Antalya Hastanesi","Antalya","07020",{"type":111,"coordinates":611},[612,613],30.69556,36.90812,{"lat":613,"lon":612},{"facility":616,"status":104,"city":617,"state":78,"zip":618,"country":561,"countryCode":78,"cosmosGeoPoint":619,"geoPoint":623,"contacts":78},"Yeditepe University Medical School Hospital","Istanbul","31755",{"type":111,"coordinates":620},[621,622],28.94966,41.01384,{"lat":622,"lon":621},{"facility":625,"status":104,"city":617,"state":78,"zip":626,"country":561,"countryCode":78,"cosmosGeoPoint":627,"geoPoint":629,"contacts":78},"Koc University Hospital","34010",{"type":111,"coordinates":628},[621,622],{"lat":622,"lon":621},{"facility":631,"status":104,"city":617,"state":78,"zip":632,"country":561,"countryCode":78,"cosmosGeoPoint":633,"geoPoint":635,"contacts":78},"Goztepe Prof. Dr. Suleyman Yalcin City Hospital","34722",{"type":111,"coordinates":634},[621,622],{"lat":622,"lon":621},{"facility":637,"status":104,"city":638,"state":78,"zip":639,"country":561,"countryCode":78,"cosmosGeoPoint":640,"geoPoint":644,"contacts":78},"Mersin City Education and Research Hospital","Mersin","33330",{"type":111,"coordinates":641},[642,643],34.63886,36.81196,{"lat":643,"lon":642},{"facility":646,"status":104,"city":647,"state":78,"zip":648,"country":561,"countryCode":78,"cosmosGeoPoint":649,"geoPoint":653,"contacts":78},"Sakarya Training and Research Hospital","Sakarya","54290",{"type":111,"coordinates":650},[651,652],32.07583,39.50333,{"lat":652,"lon":651},{"facility":655,"status":104,"city":656,"state":78,"zip":657,"country":658,"countryCode":659,"cosmosGeoPoint":660,"geoPoint":664,"contacts":78},"Royal Free Hospital","London","NW3 2QG","United Kingdom","UK",{"type":111,"coordinates":661},[662,663],-0.12574,51.50853,{"lat":663,"lon":662},{"facility":666,"status":104,"city":656,"state":78,"zip":667,"country":658,"countryCode":659,"cosmosGeoPoint":668,"geoPoint":670,"contacts":78},"Royal Marsden Hospital","SW3 6JJ",{"type":111,"coordinates":669},[662,663],{"lat":663,"lon":662},{"facility":672,"status":104,"city":673,"state":78,"zip":674,"country":658,"countryCode":659,"cosmosGeoPoint":675,"geoPoint":679,"contacts":78},"Northern Centre for Cancer Care","Newcastle upon Tyne","NE7 7DN",{"type":111,"coordinates":676},[677,678],-1.61396,54.97328,{"lat":678,"lon":677},{"facility":681,"status":104,"city":682,"state":78,"zip":683,"country":658,"countryCode":659,"cosmosGeoPoint":684,"geoPoint":688,"contacts":78},"Royal Marsden Hospital-Sutton","Sutton","SM2 5PT",{"type":111,"coordinates":685},[686,687],-0.2,51.35,{"lat":687,"lon":686},{"type":690,"investigatorFullName":78,"investigatorTitle":78,"investigatorAffiliation":78,"oldNameTitle":78,"oldOrganization":78},"SPONSOR",[692],{"name":693,"class":6},"MediLink Therapeutics (Suzhou) Co., Ltd.","100601517","phase-1-a-clinical-trial-to-test-if-an-investigational-combination-therapy-with-bnt326-and-bnt327-is-safe-and-potentially-beneficial-for-people-with-advanced-non-small-cell-lung-cancer-nsclc-100601517",false,"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)","A Phase Ib\u002FII, Multi-site, Open-label, Dose Finding Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT326 in Combination With BNT327 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified):\n\n* Aged ≥18 years at the time of giving informed consent.\n* Have measurable disease defined by RECIST v1.1.\n* All participants have to provide a tumor tissue sample (e.g. Formalin-fixed paraffin-embedded \\[FFPE\\] slides or block) from archival tissue. Alternatively, a fresh biopsy should be collected, unless medically not justifiable to be conducted.\n* Have Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Have adequate organ and bone marrow function within 7 days before randomization\u002Fenrollment.\n* Have advanced (i.e., metastatic or locally recurrent where local therapy with curative intent is not possible) non-squamous or squamous (all cohorts) or only non-squamous (Cohort D2) NSCLC.\n\nCohort-specific inclusion criteria\n\nPart 1, 2L+, squamous or non-squamous NSCLC, AGA-negative\u002Fpositive, any PD-L1\n\n* for AGA-negative NSCLC only:\n\n  * Have no actionable genomic alterations, such as EGFR mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, or other genomic alterations for which targeted molecular therapies are available.\n  * Have experienced relapse or progression during or after treatment with standard systemic therapy in the advanced\u002Fmetastatic setting or discontinued from prior therapy due to intolerance.\n  * Participants must have received 1 to 3 lines of systemic treatment, which can include anti-PD-1\u002FPD-L1 therapy, chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently or sequentially. However, chemotherapy treatment must be limited to 2 lines or less.\n* for AGA-positive NSCLC only (excluding EGFR activating mutation):\n\n  * Have documented positive test results for one or more actionable genomic alteration: EGFR (other than activating mutations), ALK, ROS proto-oncogene 1 (ROS1), gene encoding the hepatocyte growth factor receptor (MET), human gene that encodes a protein called B-Raf (BRAF), rearranged during transfection (RET), neurotrophic tropomyosin-receptor kinase (NTRK), human epidermal growth factor receptor 2 (HER2), Kirsten rat sarcoma virus (KRAS), or other genomic alteration with available targeted therapy.\n  * Must have received at least one prior systemic therapy for advanced disease, which must have included targeted treatment for actionable genomic alterations, which include alterations such as EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other alterations for which targeted therapies are available as a part of local SoC.\n  * Participants may have received between 1 to 3 lines of systemic treatment of anti-PD-1\u002FPD-L1 therapy, chemotherapy, and\u002For anti-angiogenic agents. These treatments may be administered concurrently (including with TKI) or sequentially. However, chemotherapy treatment must be limited to 2 lines or less.\n  * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n* for AGA-positive NSCLC only (with EGFR activating mutation):\n\n  * Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).\n  * Participants must have received one or two prior lines of systemic therapy for advanced and\u002For metastatic disease, which must include treatment with an approved EGFR TKI, with at least one being a third-generation EGFR TKI.\n  * Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1.\n  * Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced\u002Fmetastatic disease.\n  * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n\nPart 2a (Cohort A), 2L+, squamous or non-squamous NSCLC, AGA-negative\u002Fpositive, any PD-L1\n\n* for AGA-positive NSCLC only, excluding EGFR activating mutation:\n\n  * Have documented positive test results for one or more actionable genomic alterations: EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other genomic alterations, with available targeted therapy.\n  * May have received 1 to 4 lines of systemic treatment, of which one prior systemic therapy for advanced disease must have included targeted treatment for actionable genomic alterations, which include alterations such as EGFR (other than activating mutations), ALK, ROS1, MET, BRAF, RET, NTRK, HER2, KRAS, or other genomic alterations for which targeted therapies are available as part of local SoC.\n  * Other therapies may include anti-PD-1\u002FPD-L1 therapy, chemotherapy, and anti-angiogenic agents. These treatments may be administered concurrently\u002Fin combination (including with TKI) or sequentially. However, chemotherapy treatment must be limited to 2 lines or less.\n  * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n* for AGA-positive NSCLC only, with EGFR activation mutation:\n\n  * Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).\n  * Participants must have received one or two prior lines of systemic therapy for advanced and\u002For metastatic disease, which must include treatment with an approved EGFR TKI, with at least one being a third-generation EGFR TKI.\n  * Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1.\n  * Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced\u002Fmetastatic disease.\n  * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n\nPart 2a (Cohort B), 1L, squamous or non-squamous NSCLC, AGA-negative, any PD-L1\n\n* Have no actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or other genomic alterations for which targeted molecular therapies are available.\n* Have received no systemic anti-cancer treatment in the advanced\u002Fmetastatic setting. May have received neoadjuvant and\u002For adjuvant treatment if progression to advanced\u002Fmetastatic disease occurred at least 12 months after completing such therapy and have not received treatment in the advanced\u002Fmetastatic setting.\n\nPart 2b (Cohort C), 2L+, squamous or non-squamous NSCLC, AGA-negative or EGFR activating mutation, any PD-L1\n\n* for AGA-negative NSCLC only:\n\n  * Have no actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or other genomic alterations for which targeted molecular therapies are available.\n  * Participants should have received 1 to 4 lines of systemic treatment, which can include anti-PD-1\u002FPD-L1 therapy, chemotherapy, and\u002For anti-angiogenic agents.\n* for EGFR-sensitizing mutation NSCLC only:\n\n  * Have documented positive test results for an EGFR-sensitizing mutation (EGFR-sensitizing mutation Exon 21-L858R and 19del).\n  * Have received 1 or 2 prior systemic therapies for advanced and\u002For metastatic disease with an approved EGFR TKI, which must include one third-generation anti-EGFR TKI.\n  * Participants receiving an EGFR TKI at the time of signing informed consent may continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1.\n  * Chemotherapy is permitted only if it was administered in combination with an EGFR TKI as part of a single line of therapy and as the initial (first line) treatment for advanced\u002Fmetastatic disease.\n  * May have received neoadjuvant and\u002For adjuvant treatment if progression to advanced\u002Fmetastatic disease occurred at least 6 months after completing such therapy and have experienced disease progression on or after EGFR TKI treatment administered in the advanced\u002Fmetastatic setting.\n  * Have experienced progression during or after treatment or discontinued from prior therapy due to intolerance.\n\nPart 2b (Cohort D1) 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 ≥50% and Part 2b (Cohort D2) 1L, squamous or non-squamous NSCLC, AGA-negative, PD-L1 \\\u003C50%\n\n* Have no actionable genomic alterations, such as EGFR mutations, ALK rearrangements, or other genomic alterations for which targeted molecular therapies are available.\n* Did not receive prior systemic therapy for advanced and\u002For metastatic disease.\n\nKey Exclusion Criteria (applicable to all participants and all parts):\n\n* Had disease progression on or were intolerant to prior treatment with an agent targeting HER3 (including antibody, ADC, cell therapy, and other drugs) or with a topoisomerase I inhibitor payload (including topoisomerase I inhibitor-containing ADCs). Note: For Part 2a Cohort A, prior exposure to agents targeting HER3 or topoisomerase I inhibitor payload may be allowed on a case-by-case basis after discussion with and approval by the sponsor.\n* Have an uncontrolled concomitant or intercurrent illness, that contra-indicates study participation, limits compliance with study procedures or substantially increases the risk of incurring AEs, including:\n\n  * Bleeding diathesis or active hemorrhage\n  * Active infection, including respiratory viral infection\n  * Child-Pugh class B or C cirrhosis\n  * Known pulmonary disease with significant impact in lung function and\u002For with potential risk of severe infection\n  * Oncologic emergencies or complications (e.g., malignant hypercalcemia, superior vena cava syndrome, carcinoid syndrome that is unstable and with available alternative therapies)\n  * Psychiatric or abuse condition\n  * Colitis Grade ≥2 not resolved within 72 h within the past 3 months\n* Have left ventricular ejection fraction \\\u003C50% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization\u002Fenrollment.\n* Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization\u002Fenrollment.\n* Have a history of (non-infectious) interstitial lung disease (ILD) \u002Fpneumonitis that required steroids, have current ILD\u002Fpneumonitis, or where suspected ILD\u002Fpneumonitis cannot be ruled out by imaging at screening. Asymptomatic interstitial changes caused by previous radiation therapy, chemotherapy, or other factors such as smoking are acceptable.\n* Have had exposure to protocol-specific treatments with a washout period before randomization\u002Fenrollment.\n* Are participants of childbearing potential who are pregnant or breastfeeding or are planning pregnancy within the time specified in the protocol or are potentially fertile males, who are planning to father children during the study or within the time specified in the protocol.\n* Are subject to exclusion periods from another investigational study.\n* Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP.\n* Have urine protein ≥2+ and 24-hour urine protein excretion ≥1 g. If qualitative urine protein is ≤1+, a 24-hour urine protein quantitative test is not required.\n* Have a history of Grade ≥3 immune-related adverse events that led to treatment discontinuation of a prior checkpoint inhibitor.\n* Have clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms.\n* Participants with significant risks of hemorrhage or evidence of major coagulation disorders.\n* Have active or chronic corneal disorders or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.\n\nNOTE: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":704,"type":705},420,"ESTIMATED","INTERVENTIONAL",[708,709],"PHASE1","PHASE2","This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with BNT327 in participants with relapsed, progressive as well as treatment-naïve, advanced\u002Fmetastatic non-small cell lung cancer (NSCLC).\n\nThis study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available).",[712],"Non-small Cell Lung Cancer",[714,715,716,717,718,719,720,721,722,723,724,725,726],"Combination with other investigational agents","Programmed death-ligand 1 (PD-L1)","Antibody-drug conjugate (ADC)","Human epidermal growth factor receptor 3 (HER3)","Programmed Death-1 (PD-1)","Programmed Death-1 monoclonal antibodies","Combination chemotherapy","Anti vascular endothelial growth factor-A (anti-VEGF-A)","Bispecific antibody","Immunotherapy","Dose optimization","Time to progression","Vascular endothelial growth factor (VEGF)","2026-04-29",{"date":729,"type":730},"2026-05-05","ACTUAL",{"date":732,"type":730},"2025-09-22",{"date":734,"type":705},"2030-01",{"name":5,"class":6},68]